Cardiorespiratory fitness in long-term lymphoma survivors after high-dose chemotherapy with autologous stem cell transplantation

Jo S Stenehjem*,1,2, Knut B Smeland1,9, Klaus Murbraech3,9, Harald Holte4, Stein Kvaløy1,5, Lene Thorsen1, Ingerid Arbo6, Lee W Jones7, Svend Aakhus3,6, May Brit Lund8,10 and Cecilie E Kiserud1,10

1National Resource Center for Late Effects after Cancer Treatment, Department of Oncology, Oslo University Hospital, Oslo 0424, Norway; 2Department of Research, Cancer Registry of Norway, Oslo 0304, Norway; 3Department of Cardiology, Oslo University Hospital, Oslo 0424, Norway; 4Department of Oncology, Oslo University Hospital, Oslo 0424, Norway; 5Faculty of Medicine, University of Oslo, Oslo 0316, Norway; 6Department of Circulation and Medical Imaging, NTNU, Trondheim 7491, Norway; 7Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, NY 10065, USA and 8Department of Respiratory Medicine, Oslo University Hospital, Oslo 0424, Norway

Background: Cardiorespiratory fitness as measured by peak oxygen consumption (VO\textsubscript{2peak}) is a strong predictor of longevity and may be compromised by anticancer therapy, inactivity, and smoking. We compared VO\textsubscript{2peak} among lymphoma survivors (LSs) with reference data from healthy sedentary subjects, after a 10.2-year (mean) follow-up post high-dose chemotherapy with autologous stem cell transplantation (HDT-ASCT). We further examined the association between VO\textsubscript{2peak} and treatment, physical activity, smoking, pulmonary, and cardiac function.

Methods: Lymphoma survivors treated with HDT-ASCT in Norway 1987–2008 were eligible. VO\textsubscript{2peak} was assessed by cardiopulmonary exercise testing. Pulmonary function testing and echocardiography were also conducted. Data on treatment, physical activity, and smoking were collected from hospital records and questionnaires. VO\textsubscript{2peak} was compared with age–sex predicted reference data. Linear regression was used to associate clinical factors with VO\textsubscript{2peak} cross-sectionally.

Results: A total of 194 LSs without heart failure were studied. Mean VO\textsubscript{2peak} was 4.5% and 7.7% below norms in females and males, respectively. Twenty-two percent had impaired (\(<80\%\) predicted) VO\textsubscript{2peak}. Decreasing VO\textsubscript{2peak} was associated with impaired diffusion capacity and current smoking, while physical activity level and VO\textsubscript{2peak} were positively associated.

Conclusion: We suggest increased attention towards physical activity counseling and smoking cessation advice to preserve cardiorespiratory fitness in LSs after HDT-ASCT. Patients with impaired diffusion capacity may benefit from subsequent monitoring to detect pulmonary vascular diseases.

High-dose chemotherapy with autologous stem cell transplantation (HDT-ASCT) has been a treatment option for Hodgkin (HL) and non-Hodgkin lymphomas (NHL) since the mid-1980 (Linch \textit{et al}, 1993; Schmitz \textit{et al}, 2002). The number of lymphoma survivors (LSs) post HDT-ASCT has been steadily growing as treatment regimens and indications have evolved (Schmitz \textit{et al}, 1996).

*Correspondence: Dr JS Stenehjem; E-mail: jo.stenehjem@kreftregisteret.no
9These authors share co-second authorship.
10These authors share co-senior authorship.

Received 28 January 2016; revised 4 April 2016; accepted 16 May 2016; published online 28 June 2016

© 2016 Cancer Research UK. All rights reserved 0007 – 0920/16
In recent years, significant improvements in 5-year survival have been reported for patients receiving this therapy ranging 59–73% for HL and up to 62% for NHL (Vanderwalde et al, 2013; Smeland et al, 2013a, 2015).

As survival continues to improve, the proportion of LSs with treatment-related late effects increases (Bhatia et al, 2005), and the role of effective countermeasures is becoming increasingly important. The last decade, lifestyle change after cancer has received increased attention, and physical activity and smoking cessation have been highlighted as modifiable factors that may improve the length and quality of life among cancer survivors (Demark-Wahnefried et al, 2005). Recently, high cardiorespiratory fitness in male cancer survivors was associated with a one-third risk reduction of cancer mortality, compared with those with low cardiorespiratory fitness (Lakoski et al, 2015).

Cancer therapy may cause damage to organs involved in the transport or use of oxygen, and cardiac and pulmonary late effects related to pre HDT-ASCT therapies such as doxorubicin, bleomycin, and mediastinal irradiation are well known (Lund et al, 1996a, b; Murbraeck et al, 2015). Such treatment-induced impairments, together with physical inactivity, might reduce cardiorespiratory fitness considerably in cancer survivors (Jones et al, 2009; Lakoski et al, 2012). Measurement of peak oxygen uptake (VO2peak) by cardiopulmonary exercise testing represents the gold standard assessment of cardiorespiratory fitness, and is useful to assess the global effect of these impairments on cardiorespiratory fitness (Jones et al, 2008). Further, reduced cardiorespiratory fitness is a strong and inversely related predictor of adverse cardiovascular events in LSs (Adams et al, 2004; Jones et al, 2014). Therefore, preserving cardiorespiratory fitness by physical activity might be life-prolonging in intensively treated cancer survivors.

The present study is, to our knowledge, the first to systematically address cardiorespiratory fitness among long-term LSs after HDT-ASCT. Our primary aim was to compare VO2peak with data from a healthy, sedentary reference population. Second, we examined VO2peak according to treatment, physical activity, smoking, pulmonary impairment, cardiac function, and haemoglobin level among the LSs.

**Materials and Methods**

**Study population.** The study population was recruited from all HL and NHL survivors treated with HDT-ASCT in Norway between 1987 and 2008 (Smeland et al, 2013b). A total of 399 LSs aged 18 years or older at HDT-ASCT, who were resident in Norway by March 2012, and not currently undergoing active treatment for relapsed disease, were eligible and invited to participate. After an average follow-up of 10.2 (range 3–25) years since HDT-ASCT, the participants were asked to attend an outpatient visit between March 2012 and March 2014, which included a symptom-limited cardiopulmonary exercise test, a pulmonary function test, echocardiography, blood sampling, and a questionnaire. The participants were recruited from Oslo University Hospital (OUH) (n = 159) and St Olav’s University Hospital (Trondheim) (n = 35).

The study was approved by the South East Regional Committee for Medical and Health Research Ethics. Written informed consent was obtained from all participants.

**Treatment.** Treatment data were collected from medical records and databases at OUH and St Olav’s University Hospital. The total number of treatment lines of chemotherapy given before HDT-ASCT was registered (1, 2, or ≥ 3). During 1987–1995, total body irradiation (TBI, 1.3 Gy twice daily for 5 consecutive days with lung shielding for two doses) followed by high-dose cyclophosphamide (60 mg kg⁻¹ for 2 days) constituted the high-dose regimen. From 1995 onwards, the conditioning regimen was constrained to chemotherapy only, including carmustine, etoposide, cytarabine, and melphalan (BEAM). Cumulative doses of chest radiotherapy (RT) and chemotherapy were calculated and divided into categories: chest RT (unexposed, 1–13 Gy; >13–65 Gy), doxorubicin (<300 mg m⁻²; 300–399 mg m⁻²; 400–775 mg m⁻²), cyclophosphamide (0–3.49 g m⁻²; 3.50–5.99 g m⁻²; 6.00–12.30 g m⁻²), and bleomycin (unexposed, 1–12 international units (IU) 10⁴/m², >12–21 IU 10⁴/m²). Daunorubicin doses were converted to doxorubicin isotoxic doses using a conversion factor of 0.83 (Fullbright, 2011).

**Symptom-limited cardiopulmonary exercise testing.** Cardiopulmonary exercise testing and pulmonary function tests were performed on a SensorMedics Vmax unit (Viasys Respiratory Care Inc., Yorba Linda, CA, USA) with an Ergoline 839E bicycle (Monarch Exercise AB, Vansbro, Sweden). The gas exchange units were calibrated daily. During exercise testing, 12-lead electrocardiography, gas exchange, and ventilatory variables were monitored continuously, and testing was continued until exhaustion (respiratory exchange ratio (RER) > 1.10). The test consisted of three phases: a 2-minute warm-up (20–50 Watt workload), an incremental exercise phase of 8–12 min until exhaustion, and a 2-min recovery (American Thoracic Society; American College of Chest Physicians, 2003). VO2peak was the primary outcome and was recorded together with peak oxygen pulse, maximum ventilation, maximum workload, RER, and perceived exertion (Borg scale). Following the procedure of Jones et al (2010), percent-predicted VO2peak was calculated by dividing the measured values of our patients by those derived from age-sex dependent regression equations of VO2peak from a healthy sedentary population (Fitzgerald et al, 1997; Wilson and Tanaka, 2000). Impaired VO2peak was defined using the percent-predicted scale to account for sex-age difference, and set to <80% of predicted. Height and weight were measured, and body mass index (BMI) was calculated as kg m⁻².

**Pulmonary function.** Pulmonary function tests included dynamic spirometry, determination of static lung volumes, and gas diffusion capacity (Macintyre et al, 2005; Miller et al, 2005; Wanger et al, 2005). Recorded spirometric variables were forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1), and FEV1/FVC. Static lung volume was recorded as total lung capacity (TLC). Gas diffusion was expressed by the transfer factor of the lungs for carbon monoxide (DLCO). Percentages of predicted normal lung function values were calculated based on the reference values recommended by the ERS (Quanjer et al, 1993). Pulmonary function was dichotomised according to obstructive impairment (FEV1 < 80% of predicted and FEV1/FVC < 0.7), restrictive impairment (TLC and FVC < 80% of predicted, for 8 patients TLC data were missing and only FVC data were used to define restrictive impairment), and diffusion capacity impairment (DLCO < 80% of predicted). These cutpoints correspond to the lower 5th percentiles in the reference material recommended by the ERS.

**Echocardiography.** Left ventricular ejection fraction (LVEF) was assessed by Simpson’s biplane rule (Lang et al, 2005), and left ventricular systolic dysfunction (LVSD) was defined as a LVEF of <50% (Davies et al, 2001). Patients with heart failure (HF), defined as current or prior symptoms according to Hunt et al, (2009) were excluded to more clearly elucidate the influence of other factors than cardiac output on VO2peak (Basset and Howley, 2000). The echocardiographic examination has been described in detail elsewhere (Murbraeck et al, 2015).
Blood sampling. Blood samples were collected at 0800 h, and analysed for haemoglobin (Hb) level among other parameters. Anaemia was defined as Hb levels < 11.7 g dL⁻¹ (women) and < 13.4 g dL⁻¹ (men) (Rodgers et al, 2008).

Questionnaire. Self-reported physical activity was recorded as frequency (never, <1/week, 1/week, 2–3/week, almost daily), intensity (low, moderate, vigorous), and duration (<15 min, 15–29 min, 30 min–1 h, >1 h), and has been validated previously (Kurtze et al, 2008). Minutes per week of physical activity (0–100, 101–180, 181–375) was calculated as a product of the frequency and duration variables. A summary score, reflecting overall physical activity level, was calculated by the following equation: (frequency/5) + (intensity/3) + (duration/4), yielding an ordinal variable (range 1.18–3.00) that was categorised into three equally sized thirds (low, medium, high), where inactive patients were placed in the low physical activity group (Nilsen et al, 2008). According to the World Health Organization (WHO) guidelines on physical activity, those who reported ≥150 min week⁻¹ of moderate intensity or ≥75 min week⁻¹ of vigorous intensity was categorised as ‘meeting guidelines’ and the rest as ‘not meeting guidelines’. Smoking status was recorded as ‘never’, ‘former’, or ‘current’.

Statistical analysis. Data are presented as mean ± s.d., median (ranges), or numbers (%). Paired and independent samples t-tests were used for mean comparisons of normally distributed data, the Wilcoxon rank-sum test was used to compare ordinal data, and the Chi-square test was used to compare categorical data. Linear regression was used to estimate regression coefficients (RCs) with corresponding 95% confidence intervals (CIs) and P-values. VO₂peak, maximum ventilation, and maximum workload were examined in uni- and multivariable regression models according to relevant explanatory variables (specified in Table 3 and Supplementary Table S1, and Figure 3). After performing linear regression, the post-estimation command ‘margins’ of Stata 14 was used as described by Mitchell (2012) to derive adjusted means of VO₂peak according to physical activity level across categories of cumulative doxorubicin, adjusted for gender, age at examination, BMI, smoking, and diffusion capacity.

Tests for significance were two-sided and P-values of <0.05 were considered as statistically significant. Variables with P≤0.05 in the univariable models or that were considered clinically relevant were included in the multivariable models. Tests for trend across categories were performed by entering categorical variables as continuous variables in the models. Data analyses were performed using Stata version 14 (StataCorp, College Station, TX, USA).

RESULTS

A total of 194 survivors of HL (21%) and NHL (79%), who completed exercise, pulmonary function, and echocardiographic testing, were included in the present analysis (Figure 1). Primary diagnosis, gender, age at survey, time from HDT-ASCT to survey, chest RT, and chemotherapy (cyclophosphamide and doxorubicin) did not differ between participants and non-participants (results not shown). Among the participants, mean age at examination was 55 years, two-thirds were men, 17% reported current smoking, and 47% met the WHO recommendation on physical activity. In women and men, VO₂peak averaged 23.5 and 29.7 ml kg⁻¹ min⁻¹, respectively, and was impaired in 20% and 23% (Table 1).

VO₂peak in LSs after HDT-ASCT compared with the reference population. Among female participants, the percent-predicted (PP) VO₂peak averaged 95.5 (95% CI, 90.5–100.5), whereas that for males (PP 92.3, 95% CI 89.0–95.6) was significantly lower than the reference population (Figure 2). When VO₂peak was examined by level of physical activity, both the external comparison with the reference population (Figure 2) and the internal comparison (quartiles of VO₂peak, Table 2) were increasing in a dose-dependent manner. The low active LSs had significantly lower VO₂peak (females: PP 87.5, 95% CI 78.8–96.3; males PP 85.8, 95% CI 82.0–89.7) than the reference population, while the VO₂peak values of those who reported high activity did not differ significantly from the reference population (females: PP 105.6, 95% CI 94.8–116.5; males: PP 100.9, 95% CI 94.0–107.8) (Figure 2). For all physical activity measures, except intensity, there was a significant correlation with VO₂peak expressed as impaired vs normal (Table 2).

Factors associated with VO₂peak, ventilation, and workload. Table 3 shows uni- and multivariable models of factors associated with VO₂peak, maximum ventilation, and maximum workload. In the multivariable analysis, all outcomes were positively associated with an increase in physical activity level (P_trend<0.01). Current smoking (RC = 2.07, P = 0.05) and impaired diffusion capacity (RC = 2.33, P<0.01) were significantly associated with a decrease in VO₂peak. A reduction in maximum ventilation was associated with a cumulative bleomycin dose of >12–21 IU 10⁻⁷ m² (RC = 13.9, P = 0.05, compared with the unexposed) and obstructive pulmonary impairment (RC = 14.3, P<0.01). Maximum workload was positively associated with an increase in VO₂peak (RC 58.5, P<0.01) and inversely associated with impaired diffusion capacity (RC = 7.2, P = 0.03). No association with chest RT was found for any of the outcomes.

Physical activity level, doxorubicin exposure, and VO₂peak. Stratified on physical activity level, an increasing doxorubicin
| Variables | Total | Females | Males |
|-----------|-------|---------|-------|
| Participants, N (%) | 194 (100) | 69 (36) | 125 (64) |
| Age at primary lymphoma diagnosis, mean years (s.d.) | 42 (13) | 42 (14) | 42 (13) |
| Age at examination, mean years (s.d.) | 55 (12) | 54 (14) | 54 (11) |
| Time (years) since primary lymphoma diagnosis, mean (s.d.) | 12.9 (6.6) | 12.5 (6.1) | 13.1 (6.8) |
| Time (years) since HDT-ASCT, mean (s.d.) | 10.2 (5.8) | 10.8 (5.9) | 10.1 (5.9) |
| BMI, mean kg m⁻² (s.d.) | 26.3 (4.4) | 25.8 (5.3) | 26.6 (3.9) |
| Smoking, N (%) | | | |
| Never | 77 (40) | 28 (41) | 49 (39) |
| Former | 83 (43) | 27 (39) | 56 (45) |
| Current | 34 (17) | 14 (20) | 29 (16) |
| Lymphoma subtypes, N (%) | | | |
| Hodgkin lymphoma (HL) | 40 (21) | 16 (23) | 24 (19) |
| Non-Hodgkin lymphoma (NHL) | 154 (79) | 53 (77) | 101 (81) |
| Cancer treatment Lines of chemotherapy pre HDT-ASCT, N (%) | | | |
| 1 | 59 (30) | 18 (26) | 41 (33) |
| 2 | 105 (54) | 43 (62) | 62 (49) |
| >3 | 30 (16) | 8 (12) | 22 (18) |
| Type of HDT-ASCT, N (%) | | | |
| TBI + high-dose cyclophosphamide | 33 (17) | 11 (16) | 22 (18) |
| BEAM treatment | 161 (83) | 58 (84) | 103 (82) |
| Relapse post HDT-ASCT, N (%) | 40 (21) | 10 (14) | 30 (24) |
| RIC allogeneic SCT post HDT-ASCT, N (%) | 14 (7) | 4 (6) | 10 (8) |
| Chest-RT incl. TBI, mean Gy among exposed (s.d.) | 25.2 (12.2) | 25.3 (12.2) | 25.1 (11.8) |
| Chest-RT excl. TBI, mean Gy among exposed (s.d.) | 34.4 (7.9) | 33.8 (10.4) | 34.8 (6.0) |
| Doxorubicin, mean mg m⁻² (s.d.) | 4.6 (2.8) | 4.3 (2.9) | 4.7 (2.8) |
| Cyclophosphamide, mean g m⁻² (s.d.) | 32.0 (11.4) | 32.6 (10.1) | 31.7 (8.9) |
| Bleomycin, mean IU 10⁷/m² among exposed (s.d.) | 12.5 (4.8) | 13.7 (4.2) | 11.2 (5.3) |

**Peak exercise data**

| VO₂ peak, mean ml kg⁻¹ min⁻¹ (s.d.) | 27.5 (7.5) | 23.5 (6.5) | 29.7 (7.1) |
| VO₂ peak, mean ml L⁻¹ min⁻¹ (s.d.) | 2.23 (0.7) | 1.69 (0.46) | 2.57 (0.60) |
| Impaired VO₂ peak, N (%) | 43 (22) | 14 (20) | 29 (23) |
| Qpulser (N = 191), mean ml beat⁻¹ (s.d.) | 14.0 (4.3) | 10.0 (2.5) | 16.0 (3.5) |
| VE (N = 193), mean L min⁻¹ (s.d.) | 94.8 (28.2) | 71.4 (19.5) | 107.8 (23.4) |
| RER, mean VCO₂/VO₂ (s.d.) | 1.18 (0.07) | 1.19 (0.08) | 1.17 (0.06) |
| Heart rate (N = 191), mean beats min⁻¹ (s.d.) | 167 (16) | 167 (18) | 168 (14) |
| Workload, mean Watts (s.d.) | 171 (58) | 126 (41) | 196 (51) |
| Perceived exertion (N = 191), mean Borg (s.d.) | 17.5 (1.0) | 17.6 (1.0) | 17.4 (0.9) |

**Exercise behaviour (N = 191)**

| Minutes per week, N (%) | | | |
| 0–100 | 53 (27) | 18 (26) | 35 (28) |
| 101–180 | 72 (37) | 29 (42) | 43 (34) |
| 181–375 | 66 (34) | 22 (32) | 44 (35) |
| Intensity, N (%) | | | |
| Low | 85 (44) | 31 (45) | 54 (43) |
| Moderate | 90 (46) | 34 (49) | 56 (45) |
| Vigorous | 16 (8) | 4 (6) | 12 (10) |
| Summary score, N (%)* | | | |
| Low | 81 (42) | 25 (36) | 56 (45) |
| Medium | 53 (27) | 27 (39) | 26 (21) |
| High | 57 (29) | 17 (25) | 40 (32) |
| WHO physical activity recommendation met, N (%)b | 89 (47) | 35 (51) | 54 (44) |

**Pulmonary function**

| FEV₁, mean L (s.d.) | 3.03 (0.80) | 2.37 (0.50) | 3.40 (0.69) |
| FVC, mean L (s.d.) | 3.98 (1.02) | 3.06 (0.60) | 4.49 (0.83) |
| FEV₁/FVC, mean ratio-value (s.d.) | 0.76 (0.07) | 0.77 (0.07) | 0.76 (0.07) |
| TLC (N = 186), mean L (s.d.) | 6.40 (1.59) | 5.27 (1.00) | 7.05 (1.50) |
| DLCO, mean mmol kPa⁻¹ min⁻¹ (s.d.) | 7.88 (2.07) | 6.32 (1.28) | 8.74 (1.94) |
| Obstructive pulmonary function, N (%) | 16 (8) | 6 (9) | 10 (8) |
| Restrictive pulmonary function, N (%) | 12 (6) | 3 (4) | 9 (7) |
| Impaired gas diffusion capacity, N (%) | 85 (44) | 36 (52) | 49 (39) |
dose was associated with decreasing VO$_{2}$peak among the low active ($P_{\text{trend}} = 0.01$), while no such association was detected among the medium and highly active (Supplementary Table S1). Within the two highest doxorubicin dose groups (300–399 mg m$^{-2}/C_0$ and 400–775 mg m$^{-2}/C_0$), significant differences in VO$_{2}$peak were found between the high and low activity groups (Figure 3).

**DISCUSSION**

VO$_{2}$peak among the LSs was on average 4.5% (women) and 7.7% (men) lower than age–sex predicted values from the healthy, sedentary reference population. Twenty percent of male and twenty-three percent of female LSs had impaired VO$_{2}$peak. Impaired diffusion capacity and current smoking were associated with a reduction in VO$_{2}$peak. LSs who reported high levels of physical activity did, however, reach the VO$_{2}$peak level of the reference population. Further, a high physical activity level seemed to mitigate the inverse association between doxorubicin and VO$_{2}$peak. In sum, these findings underline the importance of long-term monitoring of LSs after HDT-ASCT, and highlight a need for increased focus on physical activity counseling and smoking cessation in the clinical oncology setting.

After a mean follow-up of 10.2 years since HDT-ASCT, 53% of the LSs were not meeting the physical activity recommendations and 17% were current smokers. As both are modifiable factors, they call upon oncology care providers to encourage lifestyle change. Although oncologists hold powerful roles as lifestyle promoters, and may benefit from the so-called ‘teachable moment’ provided by the diagnosis itself (Demark-Wahnefried et al, 2005), cancer survivors are often fatigued and it has proven difficult to change from an inactive to an active lifestyle. A study in Norwegian cancer survivors reported that only 12% changed from inactive to active lifestyle.
before diagnosis to active after treatment (Gjerset et al, 2011). Overweight, low educated, and smokers were associated with physical inactivity after treatment in the Gjerset et al (2011) study, and constitute subgroups that should receive more attention with respect to lifestyle counseling.

To our knowledge, only one other study has examined cardiorespiratory fitness in cancer survivors post HDT-ASCT (Tuchman et al, 2015). This study was, however, conducted in survivors of multiple myeloma, with a mean VO$_{2peak}$ of 17.5 ml kg$^{-1}$ min$^{-1}$ at the age of 60 years (Tuchman et al, 2015). Although both disease presentation and purpose/type of HDT-ASCT differ between multiple myeloma and lymphoma, we believe that the lower age and the exclusion of HF cases in the present study explain the 10 ml kg$^{-1}$ min$^{-1}$ higher mean VO$_{2peak}$. There has been published a study protocol of a planned multicentre exercise-intervention trial in lymphoma and multiple myeloma survivors after HDT-ASCT in the Netherlands (Persoon et al, 2010), but to our knowledge no analysis of cardiorespiratory fitness in LSs after HDT-ASCT has been reported to date.

Although only a modest reduction in mean VO$_{2peak}$ was observed between all patients and the reference population of healthy sedentary individuals, 43 in 194 patients had impaired VO$_{2peak}$. The larger proportion reporting low physical activity among the impaired vs the normal VO$_{2peak}$ groups (62% vs 37%, respectively) could explain the relatively high number of patients with impaired VO$_{2peak}$. The increase in VO$_{2peak}$ across levels of physical activity seen vs the reference population persisted in the internal comparison for all measures of exercise behaviour (i.e., minutes per week, intensity, summary score, and WHO recommendation). Further, in the multivariable prediction of VO$_{2peak}$ a significant trend across levels of physical activity was observed. The significant difference in VO$_{2peak}$ between high and low active LSs within the two highest doxorubicin dose groups suggests that a high physical activity level could mitigate the adverse effects of doxorubicin on VO$_{2peak}$. The inverse association between doxorubicin and VO$_{2peak}$ among low active might be ascribed to doxorubicin-induced impairments in endothelial function and change in Ca$^{2+}$ response in the skeletal muscle (Chow et al, 2006; van Norren et al, 2009), while increased capillaryisation and mitochondrial density could explain why VO$_{2peak}$ was similar among highly active across doses of doxorubicin (Lakoski et al, 2012).

On the basis of the previously reported associations between chest RT and cardiopulmonary sequelae in LSs (Lund et al, 1996b; Adams et al, 2004; Murbraech et al, 2015), an inverse association between chest RT and VO$_{2peak}$ would have been plausible but was, however, not seen in our data. This might be explained by the fact that we studied adult LSs, excluding RT-induced organ development impairments typically seen in childhood cancer survivors (Huang et al, 2011), and that only 10 (5%) patients received mantle field RT. The independent effect from current smoking on VO$_{2peak}$ is in line with results from non-cancer populations (Hirsch et al, 1985; Suminski et al, 2009).

Cardiorespiratory fitness depends on the lung’s diffusion capacity, the heart’s stroke volume, the blood’s Hb concentration, the endothelial function, and the skeletal muscle’s capillary density and number of mitochondria (Hoppeler and Weibel, 1998). In addition to HDT-ASCT, the LSs might have been through intensive treatment regimens with high cumulative doses of doxorubicin, bleomycin and for some radiotherapy, all in which have been associated with deteriorative effects on organ systems involved in the oxygen transport (Lund et al, 1996b; Chow et al, 2006; van Norren et al, 2009; Murbraech et al, 2015). To assess more precisely which organ components might have been damaged by such anticancer therapy, single-organ exams are necessary in addition to the collective assessment of VO$_{2peak}$ by cardiopulmonary exercise testing, and were recently highlighted as a need for future studies (Tuchman et al, 2015).

We performed echocardiography, pulmonary function testing, and blood sampling in order to dissect any single-organ impairments. As cardiac output is known to be the primary limiting factor for VO$_{2peak}$ (Basset and Howley, 2000), patients with HF were excluded. We only detected left ventricular systolic dysfunction in 7% of the participants, and no association was found between LVEF and VO$_{2peak}$ in the regression analysis. The pulmonary function tests revealed that 44% of our patients had impaired gas diffusion capacity, which accords with a recent study

| Table 2. Exercise behaviour by quartiles of peak oxygen uptake (VO$_{2peak}$) and by impaired vs normal VO$_{2peak}$ |
|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
| **Quartiles of VO$_{2peak}$ (ml kg$^{-1}$ min$^{-1}$)** | **P-value** | **Impaired</80% pred.)** | **Normal ≥80% pred.)** | **P-value** |
|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
| **Self-reported physical activity at examination (N = 191)** | **Quartile 1 (11.2–22.0)** | **Quartile 2 (22.1–26.9)** | **Quartile 3 (27.2–31.5)** | **Quartile 4 (31.7–47.5)** |
| Minutes per week, N (%) | **0.02** | **18 (43)** | **35 (23)** | **0.02** |
| Low | **0–100** | **17 (32.1)** | **15 (28.3)** | **17 (32.1)** | **4 (7.5)** |
| Medium | **101–180** | **21 (29.2)** | **15 (20.8)** | **17 (23.6)** | **19 (26.4)** |
| High | **181–375** | **11 (16.7)** | **16 (24.2)** | **15 (22.7)** | **24 (36.4)** |
| Intensity, N (%) | **<0.01** | **23 (55)** | **62 (42)** | **0.27** |
| Low | **27 (31.7)** | **23 (27.1)** | **23 (27.1)** | **12 (14.1)** |
| Medium | **21 (23.3)** | **21 (23.3)** | **23 (25.6)** | **25 (27.8)** |
| High | **1 (6.3)** | **2 (12.5)** | **3 (18.7)** | **10 (62.5)** |
| Summary score, N (%) | **<0.01** | **26 (62)** | **55 (37)** | **0.02** |
| Low | **26 (32.1)** | **22 (27.2)** | **23 (28.4)** | **10 (12.3)** |
| Medium | **15 (28.3)** | **12 (22.6)** | **17 (32.1)** | **9 (17.0)** |
| High | **8 (14.0)** | **12 (21.1)** | **9 (15.8)** | **28 (49.1)** |
| WHO recommendation, N (%) | **0.02** | **26 (62)** | **55 (37)** | **0.05** |
| Not meeting | **32 (31.4)** | **27 (26.5)** | **27 (26.5)** | **16 (15.7)** |
| Meeting | **17 (19.1)** | **19 (21.4)** | **49 (25.7)** | **47 (24.6)** |

Abbreviations: VO$_{2}$ — volume oxygen; WHO — World Health Organization.

*Percentages tabulated row-wise.

+Percentages tabulated column-wise.

Combining information on frequency, duration, and intensity.

50 min week$^{-1}$ of moderate intensity or 75 min week$^{-1}$ of vigorous intensity.
**Table 3. Peak oxygen uptake (VO₂peak), ventilation and workload associated with treatment exposures and other characteristics; presented as regression coefficients with P-values**

|                      | Univariable RC (P-value) | Multivariable RC (P-value) | Univariable RC (P-value) | Multivariable RC (P-value) | Univariable RC (P-value) | Multivariable RC (P-value) |
|----------------------|--------------------------|----------------------------|--------------------------|----------------------------|--------------------------|----------------------------|
| VO₂peak (ml kg⁻¹ min⁻¹) |                          |                            |                          |                            |                          |                            |
| Female gender        | −6.27 (<0.01)            | −5.47 (<0.01)              | −36.5 (<0.01)            | −33.3 (<0.01)              | −70.8 (<0.01)            | −12.0 (0.01)              |
| Age at examination (years) | −0.29 (<0.01)          | −0.28 (<0.01)              | −0.8 (<0.01)             | −0.7 (<0.01)              | −2.1 (<0.01)            | −0.6 (<0.01)              |
| BMI (kg·m⁻²)         | −0.37 (<0.01)            | −0.53 (<0.01)              | 0.7 (0.11)               |                            | 1.7 (0.07)              |                            |
| Smoking              |                          |                            |                          |                            |                          |                            |
| Never                | 0 (reference)            | 0 (reference)              | 0 (reference)            | 0 (reference)             | 0 (reference)           | 0 (reference)             |
| Former               | −2.19 (0.06)             | −0.41 (0.61)               | 2.3 (0.6)                |                            | 12.2 (0.188)           | 1.2 (0.74)                |
| Current              | −2.91 (0.06)             | −2.07 (0.05)               | −8.2 (0.16)              |                            | −26.3 (0.03)           | −4.6 (0.32)               |
| Years since diagnosis | 0.02 (0.78)              |                            | 0.4 (0.19)               |                            | 0.2 (0.79)             |                            |
| Years since HDT-ASCT | 0.06 (0.49)              |                            | 0.5 (0.14)               |                            | 0.7 (0.33)             |                            |
| Trend across lines of chemotherapy pre HDT-ASCT | 0.49 (0.55)              |                            | 1.5 (0.63)               |                            | 3.1 (0.62)             |                            |
| Type of HDT-ASCT regimen |                          |                            |                          |                            |                          |                            |
| TBI + high-dose cyclophosphamide | −0.17 (0.91)          |                            | −3.8 (0.48)              |                            | −2.8 (0.80)           |                            |
| BEAM (ref.)          | 0 (reference)            |                            | 0 (reference)            |                            | 0 (reference)           |                            |
| Relapse post HDT-ASCT (ref. no relapse) | −0.13 (0.92)          |                            | −3.9 (0.44)              |                            | −12.5 (0.23)           |                            |
| Chest RT (N)         |                          |                            |                          |                            |                          |                            |
| Unexposed (120)      | 0 (reference)            |                            | 0 (reference)            |                            | 0 (reference)           |                            |
| 1–13 Gy (32)         | 0.86 (0.57)              |                            | 6.0 (0.29)               |                            | 7.9 (0.5)             |                            |
| >13–65 Gy (42)       | 1.75 (0.19)              |                            | 3.4 (0.5)                |                            | 15.1 (0.15)           |                            |
| P-trend              | 0.18                     |                            | 0.39                     |                            | 0.14                   |                            |
| Doxorubicin (N)       |                          |                            |                          |                            |                          |                            |
| <300 mg·m⁻² (69)     | 0 (reference)            |                            | 0 (reference)            |                            | 0 (reference)           |                            |
| 300–399 mg·m⁻² (51)  | −2.32 (0.09)             | −0.87 (0.35)               | −8.2 (0.12)              | 0.4 (0.90)                | 18.9 (0.08)           | 2.6 (0.51)                |
| 400–775 mg·m⁻² (74)  | 0 (reference)            |                            | 0 (reference)            |                            | 0 (reference)           |                            |
| P-trend              | 0.22                     | 0.15                      | 0.23                     | 0.83                     | 0.26                   | 0.1                      |
| Cyclophosphamide (N) |                          |                            |                          |                            |                          |                            |
| (if HDT-ASCT)        |                          |                            |                          |                            |                          |                            |
| 0–3.49 g·m⁻¹ (56)    | 0 (reference)            |                            | 0 (reference)            |                            | 0 (reference)           |                            |
| 3.50–5.99 g·m⁻¹ (58) | −0.48 (0.72)             |                            | −0.1 (0.98)              |                            | 1.9 (0.86)             |                            |
| 6.00–12.30 g·m⁻¹ (70) | −1.35 (0.32)            |                            | −2.5 (0.63)              |                            | −6.2 (0.55)            |                            |
| P-trend              | 0.31                     |                            | 0.61                     |                            | 0.53                   |                            |
| Bleomycin* (N)       |                          |                            |                          |                            |                          |                            |
| Unexposed (18)       | 0 (reference)            |                            | 0 (reference)            |                            | 0 (reference)           |                            |
| 1–12 IU··m⁻² (12)    | −1.44 (0.61)             | −0.91 (0.63)               | −0.5 (0.96)              | 5.5 (0.43)                | 14.6 (0.50)           | 6.8 (0.41)                |
| >12–21 IU··m⁻² (11)  | −1.88 (0.51)             | −2.16 (0.26)               | −15.9 (0.14)             | −13.9 (0.05)              | 27.4 (0.22)           | 13.7 (0.09)               |
| P-trend              | 0.2                      | 0.40                      | 0.82                     | 0.34                     | 0.47                   | 0.78                      |
| VO₂peak (l·min⁻¹)    |                          |                            |                          |                            |                          |                            |
| Physical activity level |                          |                            |                          |                            |                          |                            |
| Low                  | 1.47 (0.23)              | 1.74 (0.05)                | 2.5 (0.6)                | 7.4 (0.03)                | 14.9 (0.12)           | 12.8 (0.01)               |
| Medium               | 5.85 (<0.01)             | 4.43 (<0.01)               | 15.8 (<0.01)             | 12.5 (<0.01)              | 48.2 (<0.01)           | 17.6 (<0.01)               |
| High                 | 0.01 (0.92)              |                            | −0.4 (0.31)              |                            | −0.2 (0.80)            |                            |
| Restrictive pulmonary function impairment (ref. no impairment) | 0.01 (0.1)              |                            | 1.5 (0.857)              |                            | 0.4 (0.98)            |                            |
| Obstructive pulmonary function impairment (ref. no impairment) | −3.99 (0.04)           | −1.80 (0.17)               | −19.2 (0.01)             | −14.3 (<0.01)            | −23.3 (0.13)           |                            |
| Diffusion capacity impairment (ref. no impairment) | −3.90 (<0.01)           | −2.33 (<0.01)               | −14.1 (<0.01)             | −4.6 (0.11)            | −40.9 (<0.01)           | −7.2 (0.03)               |
| LVEF (%)             | 0.01 (0.92)              |                            | −0.4 (0.31)              |                            | −0.2 (0.80)            |                            |
| Haemoglobin (g·dl⁻¹)  | 2.08 (<0.01)             | 0.57 (0.14)                | 10.6 (<0.01)             | 1.9 (0.19)                | 24.8 (<0.01)           | 2.6 (0.12)               |

Abbreviations: BEAM = carmustine, etoposide, cytarabine, and melphalan; BMI = body mass index; HDT-ASCT = high-dose therapy with autologous stem cell transplantation; IU = international units; LVEF = left ventricular ejection fraction; RC = regression coefficient; RT = radiotherapy; TBI = total body irradiation; VO₂peak = volume oxygen. Bold: RCs and P-values represent statistical significance at a 0.05 level.

*Unexposed group split into NHL and HL patients, using unexposed HL patients as a reference (coefficient for unexposed NHL patients (n = 153) not shown).

by Armeanian et al (2015) on long-term pulmonary function in childhood cancer survivors, where impaired diffusion capacity (defined as <75% predicted) was detected in 35% of the patients. Impaired gas diffusion capacity was independently associated with reduced VO₂peak and workload in the regression analysis. Although, the diffusive capacity of the lung is oversized in terms of adequate oxygen saturation of the arterial blood in healthy individuals (Basset and Howley, 2000), our data showed that cardiorespiratory fitness among LsS without HF was indeed limited by impaired diffusion capacity. Although neither LVEF nor Hb concentration was independently associated with VO₂peak, we cannot rule out that these factors have contributed in conjunction...
with impaired diffusion capacity and collectively reduced cardiorespiratory fitness in our patients as compared with the reference population.

Strengths of the present study include the large study population of only LSs after HDT-ASCT, in which cardiorespiratory fitness has not been reported on previously, and further the high-quality data from hospital records, from thorough medical exams, and from a validated questionnaire on physical activity. Further, the participants did not differ from non-participants, which strengthen the external validity and the generalisability of our results.

Our study was, however, limited to a cross-sectional analysis as we lacked pre-diagnostic data, and could not identify causal factors of cardiorespiratory fitness. Survival and risk of death analyses according to cardiorespiratory fitness were yet not possible due to the short period of time since testing and examination, but are warranted and will further elucidate whether preservation of cardiorespiratory fitness may prolong survival and reduce mortality in LSs after HDT-ASCT.

In summary, our data suggest that highly physically active LSs after HDT-ASCT could counteract the adverse effects from intensive anticancer treatment and reach the VO2peak level of a sedentary, healthy reference population. Impaired diffusion capacity and current smoking were independent factors associated with decreasing VO2peak. We therefore suggest increased attention towards physical activity counseling/interventions and smoking cessation advice in this patient group. Individuals with impaired diffusion capacity may benefit from subsequent monitoring to detect pulmonary vascular diseases.

ACKNOWLEDGEMENTS

We thank Unn-Merete Fagerli, MD PhD, and Torgeir Wethal, MD PhD, for their contribution in patient recruitment and clinical assessment at St Olavs University Hospital. We thank Ronnie Babigumira, MSc, and Linda Vos, PhD, at the Cancer Registry of Norway for advice on data management and statistics. The study was supported by South-Eastern Norway Regional Health Authority, and received no funding from the medical industry. LWJ is supported by grants from the US National Cancer Institute and AKTIV Against Cancer. HH is in part supported by a grant from the Norwegian Cancer Society.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

REFERENCES

Adams MJ, Lipsitz SR, Colan SD, Tarbell NJ, Treves ST, Diller L, Greenbaum N, Mauch P, Lipshultz SE (2004) Cardiovascular status in long-term survivors of Hodgkin’s disease treated with chest radiotherapy. J Clin Oncol 22(15): 3139–3148.

Armenian SH, Landier W, Francisco L, Herrera C, Mills G, Siyahian A, Supab N, Wilson K, Wolfson JA, Horak D, Bhatia S (2015) Long-term pulmonary function in survivors of childhood cancer. J Clin Oncol 33(14): 1592–1600.

American Thoracic Society; American College of Chest Physicians (2003) ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med 167(2): 211–277.

Bassett Jr DR, Howley ET (2000) Limiting factors for maximum oxygen uptake and determinants of endurance performance. Med Sci Sports Exerc 32(1): 70–84.

Bhatia S, Robison LL, Francisco L, Carter A, Liu Y, Grant M, Baker KS, Fung H, Gurney JG, McGlave PB, Nademane A, Ramsay NK, Stein A, Weisdorf DJ, Forman SJ (2005) Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study. Blood 105(11): 4215–4222.
Cardiorespiratory fitness in lymphoma survivors

Chow AY, Chin C, Dahl G, Rosenthal DN (2006) Anthracnoses cause endothelial injury in pediatric cancer patients: a pilot study. *J Clin Oncol* 24(6): 925–928.

Davies M, Hobbs F, Davis R, Kenkre J, Roalle AK, Hare R, Wosornu D, Lancashire RJ (2001) Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: a population based study. *Lancet* 358(9280): 439–444.

Demark-Wahnefried W, Aziz NM, Rowland JH, Pinto BM (2005) Riding the crest of the teachable moment: promoting long-term health after the diagnosis of cancer. *J Clin Oncol* 23(24): 5814–5830.

Fitzgerald MD, Tanaka H, Tran ZV, Seals DR (1997) Age-related declines in maximal aerobic capacity in regularly exercising vs sedentary women: a meta-analysis. *J Appl Physiol* 83(1): 160–165.

Fullbright JM (2011) Review of cardiotoxicity in pediatric cancer patients: during and after therapy. *Cardiol Res Pract* 2011: 942090.

Gjerset GM, Fosså SD, Courneya KS, Skovlund E, Thorsen L (2011) Exercise behavior in cancer survivors and associated factors. *J Cancer Surviv* 5(1): 35–43.

Hirsch GL, Sue DY, Wasserman K, Robinson TE, Hansen JE (1985) Immediate effects of cigarette smoking on cardiorespiratory responses to exercise. *J Appl Physiol* 58(6): 1975–1981.

Hoppeler H, Weibel ER (1998) Limits for oxygen and substrate transport in mammals. *J Exp Biol* 201(8): 1051–1064.

Huang TT, Hudson MM, Stokes DC, Krasin MJ, Spunt SL, Ness KK (2011) Pulmonary outcomes in survivors of childhood cancer: a systematic review. *Chest* 140(4): 881–901.

Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Joy AA, Douglas PS (2008) Exercise intolerance in cancer and the role of exercise therapy to reverse dysfunction. *Lancet Oncol* 10(6): 598–605.

Hunt SA, Eves ND, Haykowsky M, Freedland SJ, Mackey JR (2009) Quantitative assessment of cardiorespiratory fitness, skeletal muscle function, and body composition in adults with primary malignant glioma. *Cancer* 116(3): 695–704.

Hunt SA, Liu Q, Armstrong GT, Ness KK, Yasui Y, Devine K, Tonorezos E, Soares-Miranda L, Sklar CA, Douglas PS, Robison LL, Offeinger KC (2014) Exercise and risk of major cardiovascular events in adult survivors of childhood hodgkin lymphoma: a report from the childhood cancer survivor study. *J Clin Oncol* 32(32): 3643–3650.

Hunt SA, Eves ND, Haykowsky M, Freedland SJ, Mackey JR (2009) Quantitative assessment of cardiorespiratory fitness, skeletal muscle function, and body composition in adults with primary malignant glioma. *Cancer* 116(3): 695–704.

Jansz N, Rangel V, Hustvedt BE, Flanders WD (2008) Reliability and validity of self-reported physical activity in the Nord-Trendelag Health Study: HUNT 1. *Scand J Public Health* 36(1): 52–61.

Lang RM, Biering S, Devereux RB, Feiner DB, Foster A, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ. Chamber Quantification Writing Group; American Society of Echocardiography’s Guidelines and Standards Committee; European Association of Echocardiography (2005) Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. *J Am Soc Echocardiogr* 18(12): 1440–1463.

Laksoki SG, Eves ND, Douglas PS, Jones LW (2012) Exercise rehabilitation in patients with cancer. *Nat Rev Clin Oncol* 9(5): 288–296.

Laksoki SG, Willis BL, Barlow CE, Leonard D, Gao A, Radford NB, Farrell SW, Douglas PS, Berry JD, DeFina LF, Jones LW (2013) Midlife cardiorespiratory fitness, incident cancer, and survival after cancer in men: The Cooper Center Longitudinal Study. *JAMA Oncol* 1(2): 231–237.

Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, Chopra R, Milligan D, Hudson GV (1993) Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. *Lancet* 341(8852): 1051–1054.

Lund MB, Ihlen H, Voss BM, Abrahamsen AF, Nome O, Kongerud J, Stuargaard M, Forfang K (1996a) Increased risk of heart valve regurgitation after mediastinal radiation for Hodgkin’s disease: an echocardiographic study. *Heart* 75(6): 591–595.

Lund MB, Kongerud J, Boe J, Nome O, Abrahamsen AF, Ihlen H, Forfang K (1996b) Cardiopulmonary sequelae after treatment for Hodgkin’s disease: increased risk in females? *Ann Oncol* 7(2): 257–264.

MacIntyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CP, Burgos R, Coates A, Enright P, Gustafsson P, Hankinson J, Jensen R, McKay R, Miller MR, Navajas D, Pedersen OF, Pellegrino R, Wanger J (2005) Standardisation of the single-breath determination of carbon monoxide uptake in the lung. *Eur Respir J* 26(5): 720–735.

Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J. ATS/ERS Task Force (2005) Standardisation of spirometry. *Eur Respir J* 26(2): 319–338.

Mitchell MN (2012) Interpreting and Visualizing Regression Models Using Stata. Stata Press: TX, USA, pp 26–29.

Murbrack E, Smeland KB, Holte H, Loge JH, Lund MB, Wethal T, Holte E, Rösner A, Dalen H, Kvaløy S, Falks RS, Aakhus S, Kiserud CE (2015) Heart failure and asymptomatic left ventricular systolic dysfunction in lymphoma survivors treated with autologous stem-cell transplantation: A National Cross-Sectional Study. *J Clin Oncol* 33(24): 2683–2691.

Nilsen TI, Romundstad PR, Petersen H, Gunnell D, Vatten LJ (2008) Recreational physical activity and cancer risk in subsites of the colon (the Nord-Trøndelag Health Study). *Cancer Epidemiol Biomarkers Prev* 17(1): 183–188.

Persson S, Kersten MJ, Chinapaw MJ, Buffart LM, Burghout H, Schep G, Brug J, Nellet F (2010) Design of the Exercise Intervention after Stem cell Transplantation (EXIST) study: a randomized controlled trial to evaluate the effectiveness and cost-effectiveness of an individualized high intensity physical exercise program on fitness and fatigue in patients with multiple myeloma or (non-) Hodgkin’s lymphoma treated with high dose chemo-therapy and autologous stem cell transplantation. *BMJ Cancer* 10: 671.

Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC (1993) Lung volumes and forced ventilatory flows. Report working party standardization of lung function tests, European community for steel and coal. Official statement of the European respiratory society. *Eur Respir J Suppl* 16: 5–40.

Rodgers 3rd GM, Becker PS, Bennett CL, Cella D, Chanan-Khan A, Chesney C, Cleeeld C, Coccia PF, Djulbegovic B, Garst JL, Gilbreath JA, Kraut EH, Lin WC, Matulonis U, Millenson M, Reinke D, Rosenthal J, Sabbatini P, Schwartz RN, Stein RS, Vij R. National Comprehensive Cancer Network (2008) Cancer- and chemotherapy induced anemia. *J Natl Compr Canc Netw* 6(5): 536–564.

Schmitz N, Linch DC, Dreger P, Goldstone AH, Boogaerts MA, Ferrant A, Demuyck NM, Link H, Zander A, Barge A (1996) Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. *Lancet* 347(8989): 353–357.

Schmitz N, Pfisterer B, Sextro M, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, Smeland KB, Hammerstrom J, Kiserud CE, Lauritzsen GF, Blystad AK, Fagerli UM, Fluge Ø, Koch B, Hasenclever D, Goldstone AH, Diehl V. German Hodgkin’s Lymphoma Study Group; Lymphoma Working Party of the European Group for Blood and Marrow Transplantation (2002) Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. *Lancet* 359(9323): 2065–2071.

Smeland KB, Kiserud CE, Lauritsen GF, Blystad AK, Fagerli UM, Fluge O, Foss A, Hammerstrem J, Kolstad A, Loge JM, Maisenhelder M, Østenstad B, Kvaløy S, Holte H (2013a) High-dose therapy with autologous stem cell support for lymphoma in Norway 1987-2008. *Tidsskr Nor Laegeforen* 133(16): 1704–1709.

Smeland KB, Kiserud CE, Lauritsen GF, Fagerli UM, Falk RS, Fluge O, Foss A, Maisenhelder M, Kvaløy S, Holte H (2015) Conditional survival and excess mortality after high-dose therapy with autologous stem cell transplantation for adult refractory or relapsed Hodgkin lymphoma in Norway. *Haematologica* 100(6): e240–e243.
This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License.